HELP Earnings — Cybin Inc. Common Stock Post-ER Performance | BigEarnings
HELP — Cybin Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$12.18
Market Cap$889.9M
P/E—
52W Range$3.76 – $14.35
Next Earnings2026-11-12
About Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.